ABSTRACT
To better understand the changes occurring in the biopharmaceutical supply chain (BPS), I have spent the last eight years working alongside a number of key industry participants. I have spent a good amount of time working with one of the largest pharmaceutical wholesalers in the United States. During this time I interviewed hundreds of executives working for hospitals, biopharmaceutical manufacturing companies (including both clinical and commercial managers), group purchasing organizations (GPOs), and insurance companies. In addition, data were analyzed from an extensive literature review (over 750 practitioner press articles), and detailed interviews with industry thought leaders took place over this time.
